Navigation Links
Isis Reports Strong Financial Results and Highlights for Second Quarter of 2009
Date:8/6/2009

Excluding non-cash compensation expense related to stock options, operating expenses for Regulus were $2.7 million and $5.5 million for the three and six months ended June 30, 2009 compared to $1.7 million and $2.8 million for the same periods in 2008. The increase is primarily related to Regulus' continued efforts to build its team to support its internal microRNA programs and its GSK collaboration. Regulus generated a loss from operations, excluding non-cash compensation expense related to stock options, of $1.6 million and $3.8 million for the three and six months ended June 30, 2009 compared to $1.1 million and $2.1 million for the same periods in 2008.

Business Highlights

"During the last quarter, we and Genzyme made great progress regarding mipomersen on two important fronts, advancing the clinical development program and refining our regulatory strategy. We reported positive top-line results from a Phase 3 study of mipomersen in the largest, placebo-controlled Phase 3 study in homozygous FH patients. We reported that the study met its primary endpoint with a 25% reduction in LDL-C after 26 weeks of treatment with mipomersen versus 3% for placebo and all of its secondary endpoints in a highly statistically significant manner. We are very pleased with the performance of mipomersen in this study. These data are a significant milestone in the clinical development of mipomersen and support our efforts to make the drug available to patients in need," said Ms. Parshall.

"In addition to reporting data from the first of our Phase 3 trials for mipomersen, we and Genzyme refined and communicated the regulatory path for mipomersen in the United States and Europe. While the strategy continues to evolve, Genzyme plans to file the first NDA for mipomersen in the U.S. for homozygous FH in the second half of 2010, with a similar filing in Europe shortly afterwards. Data from our Phase 3 study in
'/>"/>

SOURCE Isis Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22

Related medicine technology :

1. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
2. Spherix Reports Second Quarter Earnings
3. Tapestry Reports Second Quarter 2007 Results
4. Callisto Reports on Second-Quarter 2007 Milestones
5. ImmuneRegen BioSciences Reports Material Transfer Agreement with VaxGen, Inc.
6. Vical Reports Second Quarter 2007 Financial Results, Allowance of Pandemic Influenza IND and Other Advances in Product Development Programs
7. Paper in International Journal of Oncology Reports Alfacells ONCONASE(R) Suppresses Intracellular Oxidative Stress
8. TAXUS WOMAN Study Reports Positive Clinical Outcomes for the TAXUS(R) Drug-eluting Stent in Women
9. Biopure Reports on Meeting with the FDA
10. Peregrine Reports Data Showing Bavituximabs Potential to Shrink Prostate Tumors
11. NicOx Reports TOPIGEN to Advance TPI-1020 Into Phase 2 for COPD Following Promising Clinical Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/28/2014)... 2014  Syneron Medical Ltd. (NASDAQ: ELOS ... that its new PicoWay® device has received CE Mark ... and pigmented lesions on any skin type. PicoWay is ... and 1064nm wavelengths, which utilizes Syneron,s proprietary PicoWay technology ... are trillionths of a second, known as picosecond pulses. ...
(Date:7/28/2014)... Concord Medical Services Holdings Limited ("Concord Medical" ... leading specialty hospital management solution provider and operator of ... in China , today announced that ... a special cash dividend of US$0.30 per ordinary share ... Company,s outstanding ordinary shares. The total expense for the ...
(Date:7/28/2014)...   Cardioxyl Pharmaceuticals, Inc. announced today the ... a novel potential treatment for acute decompensated heart failure ... has now initiated dosing of hospitalized patients with decompensated ... to further evaluate the drug,s safety and tolerability as ... I clinical trial evaluated the safety and tolerability of ...
Breaking Medicine Technology:Syneron Announces CE Mark for PicoWay Dual Wavelength Picosecond Laser for Tattoo Removal and Treatment of Pigmented Lesions 2Syneron Announces CE Mark for PicoWay Dual Wavelength Picosecond Laser for Tattoo Removal and Treatment of Pigmented Lesions 3Syneron Announces CE Mark for PicoWay Dual Wavelength Picosecond Laser for Tattoo Removal and Treatment of Pigmented Lesions 4Concord Medical Declares Special Dividend 2Cardioxyl Pharmaceuticals Successfully Completes First Clinical Trial For Heart Failure Drug CXL-1427 2
... plc (Nasdaq: JAZZ ) today announced that the ... Monday, February 27, 2011 at 4:30 p.m. EST/9:30 p.m. GMT. ... and review fourth quarter and full year 2011 financial results. ... accessed from the Investors section of the Jazz Pharmaceuticals, website ...
... PLEASANTON, Calif., Feb. 14, 2012  Thoratec Corporation (NASDAQ: ... circulatory support therapies to save, support and restore failing ... Leerink Swann 2012 Global Healthcare Conference on Thursday, February ... Investor Relations and Business Development, will provide an update ...
Cached Medicine Technology:
(Date:7/29/2014)... July 29, 2014 "Acceptance, Recognition, and ... who faced his own demons and wants other men to ... life partner left. A month later, he had no job, ... pay. When Raymond approached the government for assistance, the emotional ... two-year counselling program. But this approach didn’t get to the ...
(Date:7/29/2014)... 29, 2014 The Cottages Investment ... Cottages at MeadowLands Memory Care, to break ground July ... suffering from memory loss and forms of dementia, Wade ... the development of Oconto Fall’s first assisted living facility ... of The Cottages Investment Group, LLC will license the ...
(Date:7/29/2014)... Tucson-based company Outski has ... or health and wellness program, called 401(play)™. A 401(play)™ ... effective way for employees to use their earned vacation ... employees specify the amount of each paycheck to be ... benefits from offering a 401(play)™ plan to in several ...
(Date:7/29/2014)... In his latest blog post at http://www.perwickstrom.com ... Wickstrom has listed 6 ways to light the “fire” in ... avoid complacency, but for some it’s a losing battle,” commented ... powerful ways to help employees get to the next level; ... whole.” , According to Per Wickstrom, 6 ways to light ...
(Date:7/29/2014)... July 29, 2014 Launched in 2012 ... surpassed 20,000 hangovers earlier this year at its ... for expansion and the publication of research data related ... medical practice. , The only licensed medical practice dedicated ... Heaven launched in 2012 and treated thousands of patients ...
Breaking Medicine News(10 mins):Health News:SBPRA Announces the Release of Its Newest Title, "Acceptance, Recognition, and Control (A.R.C.) Against Depression" 2Health News:The Cottages Investment Group Announces Third Development Project, The Cottages at MeadowLands Memory Care, Oconto Falls 2Health News:The Cottages Investment Group Announces Third Development Project, The Cottages at MeadowLands Memory Care, Oconto Falls 3Health News:The Cottages Investment Group Announces Third Development Project, The Cottages at MeadowLands Memory Care, Oconto Falls 4Health News:Outski launches 401(play)™ Plan to Employers as Part of an Employee Benefit / Health and Wellness Program 2Health News:Per Wickstrom’s Latest Blog Post Lists 6 Ways to Light the “Fire” in Employees 2Health News:Hangover Heaven Surpasses 20,000 Hangovers 2Health News:Hangover Heaven Surpasses 20,000 Hangovers 3
... majorities of older Americans experience significant and troubling gaps ... survey, "How Does It Feel? The Older Adult Health ... Foundation, a champion for improved geriatric care and longtime ... New York University,s College of Nursing. The poll ...
... Houston, TX - Accelerated partial breast irradiation (APBI) ... increasingly popular as a treatment choice for women ... rate of later mastectomy, increased radiation-related toxicities and ... (WBI), according to researchers from The University of ...
... Taking fish-oil supplements does not significantly lower the failure rate ... The study included about 200 North American kidney-failure patients with ... which provides access to the bloodstream for hemodialysis, a process ... The patients were randomly assigned to take fish-oil capsules or ...
... would get a better bang for its health-care buck in ... more in eliminating socio-environmental risk factors than in developing medicines. ... in Children: Elevating the Role of Environment, a new paper ... in the May issue of the Future of the ...
... testing older patients, blood vitamin D levels, there,s uncertainty ... not enough. The threshold amount has become controversial as ... resolve this debate, University of Washington researchers conducted an ... D must be circulating in the blood to lower ...
... parents of teenagers, friends can have as much effect ... according to prevention researchers. "Among friendship groups with ... parents are consistent and aware of your whereabouts, and ... their (children,s) whereabouts, then you are less likely to ...
Cached Medicine News:Health News:National poll: Low cost, lifesaving services missing from most older patients' health care 2Health News:National poll: Low cost, lifesaving services missing from most older patients' health care 3Health News:APBI associated with more mastectomies, toxicities, complications, compared to traditional radiation 2Health News:APBI associated with more mastectomies, toxicities, complications, compared to traditional radiation 3Health News:Fish Oil Doesn't Cut Failure Rate of Hemodialysis Grafts 2Health News:Environment key to preventing childhood disabilities 2Health News:Researchers determine vitamin D blood level for reducing major medical risks in older adults 2Health News:It takes a village to keep teens substance free 2
The Biopro Cox comb cup is manufactured from titanium and is porous coated on the outside of the shell. The Cox comb cup accommodates a polyethylene insert....
The Plasmacup SC satisfies two important requirements: high primary stability and a low friction bearing surface....
... The integration of Trabecular Metal ... proven implant design results in a ... not only meets surgeon demands for ... provides a wide variety of shell ...
The cementless BiHAPro cup combines proven concepts with the latest innovations in cementless THR....
Medicine Products: